Biktarvy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
*<scene name='98/989308/Overall/4'>Bictegravir inhibits integrase</scene>. | *<scene name='98/989308/Overall/4'>Bictegravir inhibits integrase</scene>. | ||
[[Emtricitabine]]: | |||
*<scene name='95/959998/Cv/2'>Emtricitabine</scene>. | |||
*<scene name='95/959998/Cv/4'>Emtricitabine binding site</scene> at reverse transcriptase ([[2no6]]). Water molecules are shown as red spheres. | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 15:47, 29 August 2023
Bictegravir/emtricitabine/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. One tablet, taken orally once daily, contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.[1] It was approved for use in the United States in February 2018,[2][3] and for use in the European Union in June 2018.[4]
|
| ||||||||||
ReferencesReferences
- ↑ "Biktarvy- bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate tablet". DailyMed. 8 August 2019. Retrieved 7 March 2020.
- ↑ "Drug Approval Package: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) Tablets". U.S. Food and Drug Administration (FDA). 19 March 2018. Retrieved 7 March 2020.
- ↑ "U.S. Food and Drug Administration Approves Gilead's Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection" (Press release). Gilead. 7 February 2018.
- ↑ "Biktarvy EPAR". European Medicines Agency (EMA). 21 January 2020. Retrieved 7 March 2020.